(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2011 (14.04.2011)

PCT

(10) International Publication Number
WO 2011/044181 A1

(51) International Patent Classification:
A61K 31/54 (2006.01)

(21) International Application Number:
PCT/US2010/051553

(22) International Filing Date:
6 October 2010 (06.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/249,685 8 October 2009 (08.10.2009) US

(71) Applicant *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SCOTT, Jack, D.** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **STAMFORD, Andrew, W.** [AU/US]; 2000 Galloping Hill Road, Kenilworth, New Hampshire 07033 (US). **GILBERT, Eric, J.** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **CUMMING, Jared, N.** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **ISER-LOH, Ulrich** [DE/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **MISIASZEK, Jeffrey, A.** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **LI, Guoqing** [CN/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(74) Agents: **Sylvia A. Ayler** et al.; Merck Co., Inc., 126 East Lincoln Avenue, MS:RY60-30, Rahway, NJ 07065 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE



(I)

(57) **Abstract**: In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R^1, R^2, R^3, R^4, R^5, R^9, ring A, ring B, m, n, p, -L_1-,L_2-, and L_3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

WO 2011/044181 A1